Abstract
Background
Researchers have previously reported that mitochondrial DNA copy number (mtDNA-CN) can play different roles in microsatellite instable/mismatch repair-deficient (MSI/dMMR) and microsatellite stable/mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC). To support malignancy, dMMR CRC relies on glycolysis, while pMMR CRC favors oxidative phosphorylation. However, it is unclear whether mtDNA-CN changes are related to T cell infiltration in CRC.
Methods
The mtDNA-CN was detected by qRT-PCR in 532 patients, and the expression of CD3 and CD8 in 485 patients was detected by immunohistochemistry. The correlation between mtDNA-CN and the prognosis of CRC patients was further analyzed, and the correlation between mtDNA-CN and T lymphocyte infiltration was also analyzed. Biopsy specimens from the immune checkpoint inhibitors (ICIs) treatment cohort were obtained to verify the correlation between mtDNA-CN and the efficacy of ICIs. The effects of mtDNA-CN and MMR status on gene expression were analyzed by RNA-seq.
Results
Our results show that mtDNA-CN has inverse relationships to CRC prognosis in cases with different MMR statuses, potentially inducing the U-shaped association in CRC. The opposing correlations between mtDNA-CN and T lymphocyte infiltration in cases of dMMR CRC and pMMR CRC further suggest that mtDNA-CN might play an important role in CRC development. More importantly, cases of pMMR CRC with lower mtDNA-CN and of dMMR CRC with higher mtDNA-CN can benefit more dramatically from ICIs. Furthermore, RNA-seq revealed a link between the level of mtDNA-CN and T lymphocyte infiltration in CRC cases with different MMR statuses.
Conclusion
Our study found a potential relationship between mtDNA-CN and CRC development that differs by MMR status, potentially providing a rationale for the use of mtDNA-CN as both a predictive biomarker and a therapeutic target for ICIs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data from RNA-seq array in this study are available from the corresponding authors upon reasonable request.
References
Xie Y, Shi L, He X, Luo Y. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol Rep. 2021;9:91–104. https://doi.org/10.1093/gastro/goab010.
Lizardo DY, Kuang C, Hao S, Yu J, Huang Y, Zhang L. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside. Biochim Biophys Acta Rev Cancer. 2020;1874:188447 https://doi.org/10.1016/j.bbcan.2020.188447.
Hu H, Kang L, Zhang J, Wu Z, Wang H, Huang M, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:38–48. https://doi.org/10.1016/s2468-1253(21)00348-4.
Emiloju OE, Sinicrope FA. Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review. JAMA Oncol. 2023; https://doi.org/10.1001/jamaoncol.2023.3323.
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662–80. https://doi.org/10.1038/s41568-020-0285-7.
Li S, Na R, Li X, Zhang Y, Zheng T. Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188758 https://doi.org/10.1016/j.bbcan.2022.188758.
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27–47. https://doi.org/10.1016/j.cmet.2015.12.006.
Gentric G, Mieulet V, Mechta-Grigoriou F. Heterogeneity in cancer metabolism: new concepts in an old field. Antioxid Redox Signal. 2017;26:462–85. https://doi.org/10.1089/ars.2016.6750.
Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight. 2017;2; https://doi.org/10.1172/jci.insight.93411.
Li X, Wenes M, Romero P, Huang SC, Fendt SM, Ho PC. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16:425–41. https://doi.org/10.1038/s41571-019-0203-7.
Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345:1250684 https://doi.org/10.1126/science.1250684.
van Osch FH, Voets AM, Schouten LJ, Gottschalk RW, Simons CC, van Engeland M, et al. Mitochondrial DNA copy number in colorectal cancer: between tissue comparisons, clinicopathological characteristics and survival. Carcinogenesis. 2015;36:1502–10. https://doi.org/10.1093/carcin/bgv151.
Guo J, Zheng L, Liu W, Wang X, Wang Z, Wang Z, et al. Frequent truncating mutation of TFAM induces mitochondrial DNA depletion and apoptotic resistance in microsatellite-unstable colorectal cancer. Cancer Res. 2011;71:2978–87. https://doi.org/10.1158/0008-5472.Can-10-3482.
Sun X, Zhan L, Chen Y, Wang G, He L, Wang Q, et al. Increased mtDNA copy number promotes cancer progression by enhancing mitochondrial oxidative phosphorylation in microsatellite-stable colorectal cancer. Signal Transduct Target Ther. 2018;3:8 https://doi.org/10.1038/s41392-018-0011-z.
Hu M, Zhou M, Bao X, Pan D, Jiao M, Liu X, et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. J Clin Investig. 2021;131; https://doi.org/10.1172/jci139333.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. https://doi.org/10.1038/nature13954.
Warburg O. On the origin of cancer cells. Science. 1956;123:309–14. https://doi.org/10.1126/science.123.3191.309.
Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297–308. https://doi.org/10.1016/j.ccr.2012.02.014.
André T, Cohen R, Salem ME. Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1–9. https://doi.org/10.1200/edbk_349557.
Cui H, Huang P, Wang Z, Zhang Y, Zhang Z, Xu W, et al. Association of decreased mitochondrial DNA content with the progression of colorectal cancer. BMC Cancer. 2013;13:110 https://doi.org/10.1186/1471-2407-13-110.
Wang Y, He S, Zhu X, Qiao W, Zhang J. High copy number of mitochondrial DNA predicts poor prognosis in patients with advanced stage colon cancer. Int J Biol Markers. 2016;31:e382–e8. https://doi.org/10.5301/jbm.5000211.
Lee H, Cho JH, Park WJ, Jung SJ, Choi IJ, Lee JH. Loss of the association between telomere length and mitochondrial DNA copy number contribute to colorectal carcinogenesis. Pathol Oncol Res. 2018;24:323–8. https://doi.org/10.1007/s12253-017-0245-z.
Thyagarajan B, Wang R, Barcelo H, Koh WP, Yuan JM. Mitochondrial copy number is associated with colorectal cancer risk. Cancer Epidemiol Biomark Prev. 2012;21:1574–81. https://doi.org/10.1158/1055-9965.Epi-12-0138-t.
Guan X, Li M, Bai Y, Feng Y, Li G, Wei W, et al. Associations of mitochondrial DNA copy number with incident risks of gastrointestinal cancers: a prospective case-cohort study. Mol Carcinog. 2023;62:224–35. https://doi.org/10.1002/mc.23478.
Qu F, Liu X, Zhou F, Yang H, Bao G, He X, et al. Association between mitochondrial DNA content in leukocytes and colorectal cancer risk: a case-control analysis. Cancer. 2011;117:3148–55. https://doi.org/10.1002/cncr.25906.
Feng S, Xiong L, Ji Z, Cheng W, Yang H. Correlation between increased copy number of mitochondrial DNA and clinicopathological stage in colorectal cancer. Oncol Lett. 2011;2:899–903. https://doi.org/10.3892/ol.2011.322.
Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA. 2005;102:5992–7. https://doi.org/10.1073/pnas.0502267102.
Straus DB, Weiss A. The CD3 chains of the T cell antigen receptor associate with the ZAP-70 tyrosine kinase and are tyrosine phosphorylated after receptor stimulation. J Exp Med. 1993;178:1523–30. https://doi.org/10.1084/jem.178.5.1523.
Malka D, Lièvre A, André T, Taïeb J, Ducreux M, Bibeau F. Immune scores in colorectal cancer: where are we? Eur J Cancer. 2020;140:105–18. https://doi.org/10.1016/j.ejca.2020.08.024.
Golstein P, Griffiths GM. An early history of T cell-mediated cytotoxicity. Nat Rev Immunol. 2018;18:527–35. https://doi.org/10.1038/s41577-018-0009-3.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. https://doi.org/10.1126/science.1129139.
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39. https://doi.org/10.1016/s0140-6736(18)30789-x.
Acknowledgements
This study was supported by National Key Clinical Discipline.
Funding
The programme of Guangdong Provincial Clinical Research Center for Digestive Diseases (2020B1111170004), Science and technology key research and development plan project of Guangzhou (China) (202103000072), Natural Science Foundation of Guangdong Province (China) (2018A030313621), Science and Technology Projects in Guangzhou (202206010062), Sun Yat-sen University Clinical Research 5010 Programme (2016005), Shenzhen “San Ming Projects” Research (Grant No.lc202002).
Author information
Authors and Affiliations
Contributions
LH and LK contributed to the conception of the study and supervision. MC, HSL and WFL contributed to experiment, data collection, quality assessment and manuscript draft. PZH and FJY contributed to statistical analysis and interpretation of data. YBC, ZXL and LX contributed to the interpretation of data and revision of the manuscript draft. All authors have approved the final draft of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All human tissue samples were obtained by the Sixth Affiliated Hospital of Sun Yat-sen University and collected with written informed consent from donors. In addition, all procedures were conducted with the permission of the Institutional Review Board of the Sixth Affiliated Hospital of Sun Yat-sen University (Project number: E2021156).
Consent for publication
Not applicable.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, M., Liu, H., Liang, W. et al. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?. Br J Cancer 130, 798–807 (2024). https://doi.org/10.1038/s41416-023-02568-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-023-02568-5